GBR 600

Drug Profile

GBR 600

Alternative Names: CHR-1201; GRC 600

Latest Information Update: 10 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chromos Molecular Systems
  • Developer Glenmark Pharmaceuticals S.A.
  • Class Antiplatelets; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Acute coronary syndromes; Stroke; Thrombosis

Most Recent Events

  • 25 May 2011 Preclinical trials in Acute coronary syndromes (adjunctive threapy) in USA (Parenteral)
  • 24 Jul 2007 Glenmark Pharmaceuticals acquires CHR 1201 from Chromos Molecular Systems
  • 09 Feb 2005 Preclinical trials in Stroke in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top